Passage Bio's Upcoming Participation at Genetic Medicines Event

Author: Addison Perry Updated: 10-14-2025 07:23 AM

Passage Bio to Engage at Chardan's Annual Conference

Passage Bio, Inc. (NASDAQ: PASG), a pioneering company in genetic medicines, is poised to participate in an exciting panel discussion at Chardan's 9th Annual Genetic Medicines Conference. The event will take place in New York City, where Will Chou, M.D., the company’s president and CEO, will share insights into the latest advancements in the field on a date yet to be determined. It marks an important opportunity for the company to showcase its initiatives in the realm of neurodegenerative diseases.

Live Webcast for Virtual Attendees

Attendees unable to join in person can catch the live webcast through the Investors & News section of Passage Bio's official website. The event will also be accessible through a replay for a duration of 90 days post-conference. This approach not only enhances accessibility but also allows a broader audience to engage with the valuable information presented.

Overview of Passage Bio

Passage Bio, operating under the ticker PASG, is committed to transforming the landscape for patients suffering from neurodegenerative diseases. Their innovative research focuses on the development of one-time genetic therapies addressing the root causes of disorders like frontotemporal dementia. The lead product candidate, PBFT02, aims to increase progranulin levels to enhance lysosomal function, effectively combating disease progression.

Continued Commitment to Patients

The mission of Passage Bio extends beyond research; it encompasses a steadfast dedication to safeguarding individuals and their families from the effects of neurodegenerative conditions. By innovating therapeutic approaches, the company ensures they are at the forefront of scientific advancement, striving to protect and improve lives where it matters most.

Contact Information for Inquiries

For further details regarding the upcoming conference or company initiatives, interested parties can reach out to:

Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com

Media Inquiries:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com

Frequently Asked Questions

What is Passage Bio's main area of focus?

Passage Bio focuses on developing genetic therapies aimed at improving the lives of patients with neurodegenerative diseases.

Who will represent Passage Bio at the conference?

Will Chou, M.D., the president and CEO of Passage Bio, will represent the company at the conference.

How can I watch the event if I cannot attend in person?

A live webcast of the event will be available on Passage Bio's website, with a replay accessible for 90 days after the conference.

What is the lead product candidate of Passage Bio?

The lead product candidate is PBFT02, designed to elevate progranulin levels to treat neurodegenerative conditions.

How can I get in touch with Passage Bio for more information?

You can contact Stuart Henderson or Mike Beyer via their provided email addresses for any inquiries.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.